Annals of Surgical Oncology

, Volume 16, Issue 10, pp 2848–2855 | Cite as

Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy

  • Thomas A. d’AmatoEmail author
  • Brian L. Pettiford
  • Mathew J. Schuchert
  • Ricardo Parker
  • William A. Ricketts
  • James D. Luketich
  • Rodney J. Landreneau
Translational Research and Biomarkers



Recent adjuvant chemotherapy trials after resection of stage II and III non-small cell lung cancer (NSCLC) have identified important survival differences among patients with immunohistochemical evidence suggesting platinum resistance. No clinical information exists regarding the impact upon survival of patients treated with platinum agents who exhibit cellular evidence of their tumors’ resistance to platinum. We evaluated the utility of the extreme drug resistance (EDR) assay to predict mortality among a consecutive group of stage II through IV NSCLC patients receiving adjuvant or definitive platinum-based chemotherapy after resection or surgical biopsy.


The Extreme Drug Resistance (EDR) Assay is a clinically validated cellular proliferation assay used to test tumors for chemotherapy drug resistance. Based on response in the EDR assay, tumor specimens from stage II through IV NSCLC patients were segregated into three groups: extreme drug resistant (EDR), intermediate drug resistant (IDR), and low drug resistant (LDR). Patient survival was evaluated after platinum-based chemotherapy.


Platinum IDR/EDR was statistically significant in predicting shorter overall survival (29.8 months vs. 15.6 months) among platinum IDR/EDR-resistant patients compared with LDR patients (P = 0.047). Median survival was 16.6 months for patients with IDR/EDR to platinum and any other second agent of doublet therapy compared with patients with LDR to any platinum-based doublet where median survival was not achieved (P = 0.0268).


This is the first study to demonstrate the utility of the EDR assay to predict poor clinical outcome when platinum-based therapy is used to treat patients with biological evidence of tumor resistance to platinum. These data corroborate the finding of recent studies evaluating possible molecular correlates to poor response to specific chemotherapeutic agents.


Epidermal Growth Factor Receptor Chemotherapy Resistance Platinum Agent Tumor Biopsy Specimen Doublet Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer facts & figures 2008. American Cancer Society, Atlanta, 2008.Google Scholar
  2. 2.
    Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Winton TL, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. N Engl J Med. 2005;352:2289–97.CrossRefGoogle Scholar
  4. 4.
    Douillard J, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I–III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. ASCO annual meeting proceedings, Orlando, Florida, USA. J Clin Oncol. 2005;23:7013.Google Scholar
  5. 5.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, et al. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Mehta R, Bomstein R, Yu I-R, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treatment. 2001;66:225–37.CrossRefGoogle Scholar
  7. 7.
    Holloway R, Mehta R, Finkler N, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002;87:8–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Parker RJ, Fruehauf JP, Mehta R, et al. A prospective blinded study of predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neuro-Oncol. 2004;66:365–75.CrossRefGoogle Scholar
  9. 9.
    d’Amato TA, Landreneau RJ, McKenna RJ, et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small cell lung cancer. Ann Thor Surg. 2006;81:440–7.CrossRefGoogle Scholar
  10. 10.
    d’Amato TA, Landreneau RJ, Ricketts W, Huang W, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:352–63. CrossRefPubMedGoogle Scholar
  11. 11.
    Greene FL, Page DL, Fleming ID, et. al. AJCC cancer staging manual, 6th ed. Springer-Verlag, New York, 2002.Google Scholar
  12. 12.
    Schiller J, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Kern D, Weisenthal L. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharacologic drug exposures. J Natl Cancer Inst. 1990;82:582–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Wilbur DW, Camacho ES, Hilliard DA, et al. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer. 1992;65:27–32.PubMedGoogle Scholar
  15. 15.
    Moon YW, Choi SH, Kim YT, Sohn JH, et al. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable non-small-cell lung cancer. Cancer. 2007;109:1829–35.CrossRefPubMedGoogle Scholar
  16. 16.
    Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non–small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598 J Clin Oncol. 2004;22:1180–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group. J Clin Oncol. 2008;26:3552–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Tsao MS, Aviel-Ronen S, Ding K, Lau D, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med. 2006;355:570–80.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen HY, Yu SL, Chen CH, Chang GC, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11–20.CrossRefPubMedGoogle Scholar
  22. 22.
    Boutros PC, Lau SK, Pintilie M, Liu N, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci. 2009;106:2824–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Schwartz AM, Henson DE. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines, 2nd ed. Chest. 2007;132(3 Suppl):78S–93S.Google Scholar
  24. 24.
    d’Amato TA. Adjuvant chemotherapy and the role of chemoresistance testing for stage I non-small cell lung cancer. Thorac Surg Clin. 2007;17:287–99.CrossRefPubMedGoogle Scholar
  25. 25.
    Strauss G, Herndon J, Maddaus M, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24(18S):7007.Google Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Thomas A. d’Amato
    • 1
    Email author
  • Brian L. Pettiford
    • 2
  • Mathew J. Schuchert
    • 2
  • Ricardo Parker
    • 3
  • William A. Ricketts
    • 3
  • James D. Luketich
    • 2
  • Rodney J. Landreneau
    • 2
  1. 1.Forum Health—Western Reserve Health SystemYoungstownUSA
  2. 2.University of Pittsburgh Medical CenterPittsburghUSA
  3. 3.Oncotech, Inc.TustinUSA

Personalised recommendations